Pharvaris presented Phase 3 CHAPTER-3 trial data showing that their oral drug deucrictibant XR significantly reduced hereditary angioedema (HAE) attacks by 83% compared to placebo. The drug was well tolerated, with nearly half of patients attack-free over 24 weeks. Additional data support its safety, potential combined use with an immediate-release form, and highlight the economic burden of HAE. Pharvaris aims to offer effective oral treatments to improve disease management and reduce healthcare costs.
Pharvaris' clinical and real-world data presentation offers context for readers interested in health sector developments. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 22:11 WIB: out of 150 priced US health-sector stocks, 42 rose and 108 fell. Notable movers include ERAS at USD 15.54 with a -7.50% change and a typical hold time of 4 days, BNGO at USD 1.02 with a -7.27% change and a typical hold time of 52 days, and AXGN at USD 54.92 with a -6.33% change and a typical hold time of 18 days.
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
